BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang M. High antibiotic resistance rate: A difficult issue for Helicobacter pylori eradication treatment. World J Gastroenterol 2015; 21(48): 13432-13437 [PMID: 26730153 DOI: 10.3748/wjg.v21.i48.13432] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 45] [Article Influence: 5.1] [Reference Citation Analysis]
Number Citing Articles
1 Qaiser A, Kiani MH, Parveen R, Sarfraz M, Shahnaz G, Rahdar A, Taboada P. Design and synthesis of multifunctional polymeric micelles for targeted delivery in Helicobacter pylori infection. Journal of Molecular Liquids 2022;363:119802. [DOI: 10.1016/j.molliq.2022.119802] [Reference Citation Analysis]
2 Wang Y, Tang J, Zhou S, Liang TT, Wang FF, Ning H. Effectiveness and Safety of Rifaximin-Containing Regimens for Helicobacter pylori Eradication: Systematic Review - Are They Potential Eradication Regimens? Infect Drug Resist 2022;15:3733-49. [PMID: 35859911 DOI: 10.2147/IDR.S371131] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Sabry MM, El-fishawy AM, El-rashedy AA, El Gedaily RA. Phytochemical Investigation of Cordia africana Lam. Stem Bark: Molecular Simulation Approach. Molecules 2022;27:4039. [DOI: 10.3390/molecules27134039] [Reference Citation Analysis]
4 Zhou Y, Zhong Z, Hu S, Wang J, Deng Y, Li X, Chen X, Li X, Tang Y, Li X, Hao Q, Liu J, Sang T, Bo Y, Bai F. A Survey of Helicobacter pylori Antibiotic-Resistant Genotypes and Strain Lineages by Whole-Genome Sequencing in China. Antimicrob Agents Chemother 2022;:e0218821. [PMID: 35652644 DOI: 10.1128/aac.02188-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Jaramillo-trujillo G, Otero-regino WA, Estrada-orozco KP. Efectividad y seguridad del uso de probióticos como adyuvantes en la erradicación de Helicobacter pylori. Revisión sistemática y metaanálisis. Rev Fac Med 2022;71:e98018. [DOI: 10.15446/revfacmed.v71n2.98018] [Reference Citation Analysis]
6 Naghibzadeh N, Salmani F, Nomiri S, Tavakoli T. Investigating the effect of quadruple therapy with Saccharomyces boulardii or Lactobacillus reuteri strain (DSMZ 17648) supplements on eradication of Helicobacter pylori and treatments adverse effects: a double-blind placebo-controlled randomized clinical trial. BMC Gastroenterol 2022;22:107. [PMID: 35255819 DOI: 10.1186/s12876-022-02187-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Hosseini RS, Rahimian G, Shafigh MH, Validi M, Khaledi M, Gholipour A. Correlation between clarithromycin resistance, virulence factors and clinical characteristics of the disease in Helicobacter pylori infected patients in Shahrekord, Southwest Iran. AMB Express 2021;11:147. [PMID: 34731345 DOI: 10.1186/s13568-021-01310-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Contreras-omaña R, Escorcia-saucedo A, Velarde-ruiz Velasco J. Prevalencia e impacto de resistencias a antimicrobianos en infecciones gastrointestinales: una revisión. Revista de Gastroenterología de México 2021;86:265-275. [DOI: 10.1016/j.rgmx.2021.02.003] [Reference Citation Analysis]
9 Contreras-Omaña R, Escorcia-Saucedo AE, Velarde-Ruiz Velasco JA. Prevalence and impact of antimicrobial resistance in gastrointestinal infections: A review. Rev Gastroenterol Mex (Engl Ed) 2021;86:265-75. [PMID: 34158260 DOI: 10.1016/j.rgmxen.2021.06.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
10 Jukic I, Vukovic J, Rusic D, Bozic J, Bukic J, Leskur D, Seselja Perisin A, Modun D. Adherence to Maastricht V/Florence consensus report for the management of Helicobacter pylori infection among primary care physicians and medical students in Croatia: A cross-sectional study. Helicobacter 2021;26:e12775. [PMID: 33368852 DOI: 10.1111/hel.12775] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
11 de Souza MPC, de Camargo BAF, Spósito L, Fortunato GC, Carvalho GC, Marena GD, Meneguin AB, Bauab TM, Chorilli M. Highlighting the use of micro and nanoparticles based-drug delivery systems for the treatment of Helicobacter pylori infections. Crit Rev Microbiol 2021;47:435-60. [PMID: 33725462 DOI: 10.1080/1040841X.2021.1895721] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
12 Singh H, Chung H, Awan I, Mone A, Cooper R, Patel S, Grigoryan Z, Ishida Y, Papachristou C, Judge T, DeSipio J, Phadtare S. Designing strategies for eradication of Helicobacter pylori based on prevalence patterns of infection and antibiotic resistance in a low-income, medically underserved community in the United States. Helicobacter 2021;26:e12769. [PMID: 33167084 DOI: 10.1111/hel.12769] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
13 Damanhuri NS, Kumolosasi E, Omar MS, Razak AFA, Mansor AH. The influence of P-glycoprotein expression in the standard treatment of Helicobacter pylori infection in Sprague Dawley rats. Daru 2021;29:13-22. [PMID: 33405191 DOI: 10.1007/s40199-020-00377-2] [Reference Citation Analysis]
14 Zhang Y, Bi B, Guo X, Zhang S. Analysis of Eradication, Recurrence and Levels of 25-hydroxyvitamin D3 and Interleukin-1β in paediatric patients with Helicobacter Pylori Infection-related Gastritis. Pak J Med Sci 2020;36:1377-81. [PMID: 32968412 DOI: 10.12669/pjms.36.6.2292] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Cai Y, Wang C, Chen Z, Xu Z, Li H, Li W, Sun Y. Transporters HP0939, HP0497, and HP0471 participate in intrinsic multidrug resistance and biofilm formation in Helicobacter pylori by enhancing drug efflux. Helicobacter 2020;25:e12715. [PMID: 32548895 DOI: 10.1111/hel.12715] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
16 Shi J, Liu L, Li J, Ma X, Qiu H, Shen T. Efficacy and safety of Zuojin Pill for chronic gastritis: Protocol for a systematic review of randomized controlled trials. Medicine (Baltimore) 2020;99:e21248. [PMID: 32702906 DOI: 10.1097/MD.0000000000021248] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
17 Masetti M, Falchi F, Gioia D, Recanatini M, Ciurli S, Musiani F. Targeting the Protein Tunnels of the Urease Accessory Complex: A Theoretical Investigation. Molecules 2020;25:E2911. [PMID: 32599898 DOI: 10.3390/molecules25122911] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
18 Jukic I, Rusic D, Vukovic J, Zivkovic PM, Bukic J, Leskur D, Seselja Perisin A, Luksic M, Modun D. Correlation of registered drug packs with Maastricht V/Florence Consensus Report and national treatment guidelines for management of Helicobacter pylori infection. Basic Clin Pharmacol Toxicol 2020;126:212-25. [DOI: 10.1111/bcpt.13322] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
19 Kim BJ, Yang CH, Song HJ, Jeon SW, Kim GH, Kim HS, Kim TH, Shim KN, Chung IK, Park MI, Choi IJ, Kim JH, Kim BW, Baik GH, Han SW, Seo HE, Jung WT, Hwan Oh J, Kim SG, Lee JH, Park SK, Park BJ, Yang BR, Lee J, Kim JG. Online registry for nationwide database of Helicobacter pylori eradication in Korea: Correlation of antibiotic use density with eradication success. Helicobacter 2019;24:e12646. [PMID: 31368629 DOI: 10.1111/hel.12646] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
20 Sun Y, Zhang J. Helicobacter pylori recrudescence and its influencing factors. J Cell Mol Med 2019;23:7919-25. [PMID: 31536675 DOI: 10.1111/jcmm.14682] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
21 Kang SJ, Park B, Shin CM. Helicobacter pylori Eradication Therapy for Functional Dyspepsia: A Meta-Analysis by Region and H. pylori Prevalence. J Clin Med. 2019;8. [PMID: 31466299 DOI: 10.3390/jcm8091324] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
22 Arévalo A, Otero WA, Trespalacios AA. Helicobacter pylori: Multiple resistance in patients from Bogotá, Colombia. Biomedica 2019;39:125-34. [PMID: 31529855 DOI: 10.7705/biomedica.v39i3.4437] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Karmakar P, Gaitonde V. Promising Recent Strategies with Potential Clinical Translational Value to Combat Antibacterial Resistant Surge. Medicines (Basel) 2019;6:E21. [PMID: 30709019 DOI: 10.3390/medicines6010021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
24 Zamani M, Zamani V, Derakhshan MH, Shokri-Shirvani J. The efficacy of first-line regimens for Helicobacter pylori eradication in different continents: A systematic review and network meta-analysis protocol. Medicine (Baltimore). 2018;97:e13682. [PMID: 30558078 DOI: 10.1097/md.0000000000013682] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
25 Zanotti G, Cendron L. Structural Aspects of Helicobacter pylori Antibiotic Resistance. Adv Exp Med Biol 2019;1149:227-41. [PMID: 31016632 DOI: 10.1007/5584_2019_368] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
26 Huang B, Yan S, Chen C, Ye S. Effect of 25-hydroxyvitamin D on Helicobacter pylori eradication in patients with type 2 diabetes. Wien Klin Wochenschr 2019;131:75-80. [PMID: 30542778 DOI: 10.1007/s00508-018-1416-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
27 Siavoshi F, Saniee P, Malekzadeh R. Effective antimicrobial activity of rifabutin against multidrug-resistant Helicobacter pylori. Helicobacter 2018;23:e12531. [PMID: 30230637 DOI: 10.1111/hel.12531] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
28 Ma J, Hiratsuka T, Etoh T, Akada J, Fujishima H, Shiraishi N, Yamaoka Y, Inomata M. Anti-proliferation effect of blue light-emitting diodes against antibiotic-resistant Helicobacter pylori. J Gastroenterol Hepatol 2018;33:1492-9. [PMID: 29218793 DOI: 10.1111/jgh.14066] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
29 Angsantikul P, Thamphiwatana S, Zhang Q, Spiekermann K, Zhuang J, Fang RH, Gao W, Obonyo M, Zhang L. Coating nanoparticles with gastric epithelial cell membrane for targeted antibiotic delivery against Helicobacter pylori infection. Adv Ther (Weinh) 2018;1:1800016. [PMID: 30320205 DOI: 10.1002/adtp.201800016] [Cited by in Crossref: 67] [Cited by in F6Publishing: 73] [Article Influence: 13.4] [Reference Citation Analysis]
30 Pintar T, Kaliterna N, Carli T. The need for a patient-tailored Helicobacter pylori eradication protocol prior to bariatric surgery. J Int Med Res 2018;46:2696-707. [PMID: 29690823 DOI: 10.1177/0300060518769543] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
31 Yilmaz B, Koseoglu H, Coskun Y, Deveci M, Kekilli M. Comparison between different first-line therapy protocols in eradicating Helicobacter pylori in a region with high clarithromycin resistance. Prz Gastroenterol 2018;13:150-6. [PMID: 30002775 DOI: 10.5114/pg.2018.72732] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
32 Xiong M, Bao Y, Xu X, Wang H, Han Z, Wang Z, Liu Y, Huang S, Song Z, Chen J, Peek RM Jr, Yin L, Chen LF, Cheng J. Selective killing of Helicobacter pylori with pH-responsive helix-coil conformation transitionable antimicrobial polypeptides. Proc Natl Acad Sci U S A 2017;114:12675-80. [PMID: 29133389 DOI: 10.1073/pnas.1710408114] [Cited by in Crossref: 81] [Cited by in F6Publishing: 83] [Article Influence: 13.5] [Reference Citation Analysis]
33 Shao Y, Lu R, Yang Y, Xu Q, Wang B, Ye G. Antibiotic resistance of Helicobacter pylori to 16 antibiotics in clinical patients. J Clin Lab Anal. 2018;32:e22339. [PMID: 28984385 DOI: 10.1002/jcla.22339] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
34 Li Y, Sun Y, Wang W. Fractional order dynamics for clarithromycin against helicobacter pylori. 2017 6th Data Driven Control and Learning Systems (DDCLS) 2017. [DOI: 10.1109/ddcls.2017.8068152] [Reference Citation Analysis]
35 Geng X, Li W, Chen Z, Gao S, Hong W, Ge X, Hou G, Hu Z, Zhou Y, Zeng B, Li W, Jia J, Sun Y. The Bifunctional Enzyme SpoT Is Involved in the Clarithromycin Tolerance of Helicobacter pylori by Upregulating the Transporters HP0939, HP1017, HP0497, and HP0471. Antimicrob Agents Chemother 2017;61:e02011-16. [PMID: 28242673 DOI: 10.1128/AAC.02011-16] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
36 Musiani F, Gioia D, Masetti M, Falchi F, Cavalli A, Recanatini M, Ciurli S. Protein Tunnels: The Case of Urease Accessory Proteins. J Chem Theory Comput 2017;13:2322-31. [PMID: 28379694 DOI: 10.1021/acs.jctc.7b00042] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
37 Talebi Bezmin Abadi A. Helicobacter pylori treatment: New perspectives using current experience. Journal of Global Antimicrobial Resistance 2017;8:123-30. [DOI: 10.1016/j.jgar.2016.11.008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
38 Miura M, Ohtaka M, Hanawa M, Shimura N, Yoda Y, Suzuki S. Gastric Mucosal Atrophy Might Be Associated with the Efficacy of First-Line Therapy Using Vonoprazan for <i>Helicobacter pylori</i>. OJGas 2017;07:243-259. [DOI: 10.4236/ojgas.2017.79026] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
39 Quek C, Pham ST, Tran KT, Pham BT, Huynh LV, Luu NB, Le TK, Quek K, Pham VH. Antimicrobial susceptibility and clarithromycin resistance patterns of Helicobacter pylori clinical isolates in Vietnam. F1000Res 2016;5:671. [PMID: 27583131 DOI: 10.12688/f1000research.8239.1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
40 Zhao QF, Yuan XM, Xia H, Wu Q, Jiang KT. Pristimerin inhibits growth and induces apoptosis of gastric cancer MGC803 and SGC7901 cells. Shijie Huaren Xiaohua Zazhi 2016; 24(7): 1064-1069 [DOI: 10.11569/wcjd.v24.i7.1064] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
41 Kim SE, Park MI, Park SJ, Moon W, Kim JH, Jung K, Seo KI, Lim SK, Jung JK, Kim HJ, Yeo GE, Jeon SC, Cho DS, Han YJ. The Influence of Iron Deficiency onHelicobacter pyloriEradication. Korean J Helicobacter Up Gastrointest Res 2016;16:82. [DOI: 10.7704/kjhugr.2016.16.2.82] [Reference Citation Analysis]